Pimozide for schizophrenia or related psychoses

Area of Science:

• Psychiatry and Pharmacology
• Clinical Neuroscience
• Evidence-Based Medicine

Background:

• Pimozide, developed in the late 1960s, has been used for schizophrenia and delusional disorder.
• This review focuses on evaluating pimozide's efficacy and safety in treating psychotic disorders.

Purpose of the Study:

• To assess the clinical, social, and economic outcomes of pimozide in patients with schizophrenia, non-affective psychotic illness, and delusional disorder.
• To compare pimozide's effectiveness against other drug treatments for these conditions.

Main Methods:

• Comprehensive electronic searches of major biomedical databases (MEDLINE, EMBASE, PsycLIT) and relevant registers were conducted.
• Randomized controlled trials comparing pimozide with other treatments for schizophrenia or related disorders were included.
• Data extraction and analysis involved calculating Relative Risks (RR) and Number Needed to Treat (NNT) using a random effects model.

Main Results:

• Pimozide was found to prevent relapse in schizophrenia patients (RR 0.59).
• It showed similar efficacy to typical antipsychotics in improving global functioning and mental state.
• Adverse events included a higher likelihood of parkinsonian tremor and need for antiparkinsonian medication, but less sedation.

Conclusions:

• Pimozide is an effective antipsychotic for schizophrenia, comparable to commonly used alternatives like chlorpromazine.
• Current data does not support or refute the use of pimozide for delusional disorder.
• While effective, the increased risk of specific side effects warrants careful consideration.